Randomised, double-blind study to evaluate the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A clinical trial protocol.

Randomised, double-blind study to evaluate the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A clinical trial protocol.

In Japan, corticosteroid monotherapy has traditionally been recommended as the first-line therapy for membranous nephropathy with nephrotic syndrome. In contrast, except for Japan, rituximab is recommended as the first-line therapy for membranous nephropathy with nephrotic syndrome. This clinical tr...

Full description

Saved in:
Bibliographic Details
Main Authors: Shinobu Shimizu, Akihito Tanaka, Nao Matsuyama, Fumie Kinoshita, Kazuhiro Furuhashi, Shoichi Maruyama, PRIME Study Group
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2025-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0320070
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items